Skip to main content

EyePoint, Inc.

corporate_fare Company Profile

EyePoint, Inc.

EYPT·NASDAQ·Industrial Applications And Services·CIK 0001314102

EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for serious retinal diseases. The company utilizes its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. EyePoint's primary product candidate is DURAVYU™, an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases. DURAVYU™ combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), with the Durasert E™ drug delivery technology. Vorolanib, the active drug in DURAVYU™, acts through intracellular inhibition of all VEGF receptors, platelet-derived growth factor (PDGF), and pro-inflammatory interleukin 6 (IL-6)/JAK1 signaling for at least six months. Vorolanib has also shown neuroprotection in an in-vivo model of retinal detachment. DURAVYU™ is currently in Phase 3 pivotal trials (LUGANO and LUCIA) for wet age-related macular degeneration (wet AMD) and in Phase 3 clinical trials (COMO and CAPRI) for diabetic macular edema (DME). Enrollment in the pivotal Phase 3 clinical trials for wet AMD is complete, with data expected beginning in mid-2026. The first patient was dosed in the Phase 3 DME program in February 2026. Additional pipeline programs include EYP-2301, razuprotafib, a TIE-2 agonist, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four products approved by the U.S. Food and Drug Administration (FDA). EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

EyePoint, Inc. (NASDAQ:EYPT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 31 items for EYPT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for EYPT spans 8-K, 10-Q, 144.

Recent high-impact activity:

  • EyePoint Hit With Securities Class Action Over DURAVYU Disclosures
  • EyePoint 10-Q: Going-Concern Warning, $274.9M Nine-Month Loss, Sub-$1 Nasdaq Bid
  • EyePoint Posts $95.6M Q3 Loss, $118M Cash, Runway Into Late Q3 2027
  • EyePoint Posts $95.6M Quarterly Loss, Pins Future on DME With Cash Into Late 2027
  • EyePoint Cuts 53% of Staff, Ends Wet AMD Trials After Second Phase 3 Failure

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$31.37M
Net Income
-$231.96M
Diluted EPS
-$3.17
Op. Cash Flow
-$240.11M
Free Cash Flow
-$243.39M
Operating Income
-$243.43M
Cash & Equivalents
$101.82M
Debt / Equity
0.00×
Net Margin
-7.39×
Shares Outstanding
82.83M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-093917

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 11,020,929 shares in EYPT as of the October 30, 2026 settlement, a 48.2% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 65.5% of EYPT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)11,020,929 shares as of October 30, 2026
Change vs prior period▼ 48.2%
Days to cover1.00 at avg daily volume of 29,799,680
Daily short volume (FINRA facilities)65.5% of 2,318,482 shares on November 20, 2026
5-day average short volume67.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for EYPT, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.

Incentive Plan Share Increase Approved · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$0.2385 +1.85% today
52-week range · as of 2026-11-19 $0.2385 – $19.11
Market cap
$26.65M
Volume
4.9M (0.4× avg)
3-mo avg 13.9M
Live data · 2026-11-22 01:23 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EYPT - Latest Insights

EYPT
Nov 19, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.281969
Real-time Price: $0.238543 info
Change: -$0.043426 (-15%) info
Market Cap: $26.648M info
EYPT
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.350
Real-time Price: $0.238543 info
Change: -$0.111457 (-32%) info
Market Cap: $26.648M info
EYPT
Nov 12, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.360
Real-time Price: $0.238543 info
Change: -$0.121457 (-34%) info
Market Cap: $26.648M info
EYPT
Nov 12, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.360
Real-time Price: $0.238543 info
Change: -$0.121457 (-34%) info
Market Cap: $26.648M info
EYPT
Oct 19, 2026, 9:22 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5443
Real-time Price: $0.238543 info
Change: -$0.305757 (-56%) info
Market Cap: $26.648M info
EYPT
Oct 19, 2026, 8:08 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.6115
Real-time Price: $0.238543 info
Change: -$0.372957 (-61%) info
Market Cap: $26.648M info
EYPT
Oct 19, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.99
Real-time Price: $0.238543 info
Change: -$2.75 (-92%) info
Market Cap: $26.648M info
EYPT
Oct 19, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.99
Real-time Price: $0.238543 info
Change: -$2.75 (-92%) info
Market Cap: $26.648M info
EYPT
Sep 10, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.40
Real-time Price: $0.238543 info
Change: -$4.16 (-95%) info
Market Cap: $26.648M info
EYPT
Aug 17, 2026, 11:16 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $4.59
Real-time Price: $0.238543 info
Change: -$4.35 (-95%) info
Market Cap: $26.648M info
EYPT
Aug 17, 2026, 8:50 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.45
Real-time Price: $0.238543 info
Change: -$4.21 (-95%) info
Market Cap: $26.648M info
EYPT
Aug 17, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $15.27
Real-time Price: $0.238543 info
Change: -$15.03 (-98%) info
Market Cap: $26.648M info
EYPT
Aug 05, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.82
Real-time Price: $0.238543 info
Change: -$11.58 (-98%) info
Market Cap: $26.648M info
EYPT
Jul 30, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.99
Real-time Price: $0.238543 info
Change: -$11.75 (-98%) info
Market Cap: $26.648M info
EYPT
Jul 21, 2026, 4:44 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $13.06
Real-time Price: $0.238543 info
Change: -$12.82 (-98%) info
Market Cap: $26.648M info
EYPT
Jul 17, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $13.30
Real-time Price: $0.238543 info
Change: -$13.06 (-98%) info
Market Cap: $26.648M info
EYPT
Jul 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.30
Real-time Price: $0.238543 info
Change: -$13.06 (-98%) info
Market Cap: $26.648M info
EYPT
Jun 22, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.58
Real-time Price: $0.238543 info
Change: -$13.34 (-98%) info
Market Cap: $26.648M info
EYPT
May 14, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.30
Real-time Price: $0.238543 info
Change: -$13.06 (-98%) info
Market Cap: $26.648M info
EYPT
May 14, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $13.70
Real-time Price: $0.238543 info
Change: -$13.46 (-98%) info
Market Cap: $26.648M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets